According to MarketsandMarkets™, The global biosimilars market is projected to grow from USD 35.04 billion in 2025 to USD 72.29 billion by 2035, registering a CAGR of 7.5% during the forecast period. The market is being driven by the increasing prevalence of chronic diseases, patent expirations of high-revenue biologics, growing healthcare cost pressures, and expanding efforts to improve patient access to advanced therapies.
Browse 420 market data Tables and 58 Figures spread through 391 Pages and in-depth TOC on “Biosimilars Market”.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40
Biosimilars are increasingly being adopted as cost-effective alternatives to reference biologic medicines. Governments and healthcare systems worldwide are supporting biosimilar adoption through favorable policies and streamlined regulatory frameworks. At the same time, advances in biologics manufacturing, growing clinician acceptance, and increased investment from pharmaceutical and biotechnology companies are strengthening market opportunities.
However, persistent pricing pressure and increasing competition among manufacturers remain key challenges for market participants.
Monoclonal Antibodies Segment to Register Strong Growth
By drug class, the monoclonal antibodies (mAbs) segment accounted for the largest share of the biosimilars market in 2025 and is expected to register the highest CAGR during the forecast period.
Biosimilars of widely used monoclonal antibodies—including infliximab, rituximab, adalimumab, trastuzumab, and other emerging therapies—are gaining importance across oncology, autoimmune diseases, and other chronic conditions. Patent expirations of major biologics are creating opportunities for manufacturers to introduce competing biosimilar products, potentially increasing treatment affordability and expanding patient access.
The growing availability of mAb biosimilars is also expected to intensify competition in the biologics market and encourage healthcare systems to adopt more cost-efficient treatment strategies.
Oncology Segment Holds Largest Market Share
By indication, oncology accounted for the largest share of the biosimilars market in 2024. The high prevalence of cancer and the substantial cost of biologic oncology therapies are major factors supporting segment growth.
Biosimilars such as trastuzumab, bevacizumab, rituximab, filgrastim, epoetin alfa, and denosumab are increasingly being used in cancer treatment. Their lower cost compared with reference biologics can help healthcare systems improve access to essential therapies while managing increasing oncology expenditures.
Continued regulatory approvals, expanding clinical evidence, and growing investment in oncology R&D are expected to further strengthen the role of biosimilars in cancer care.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=40
Europe Dominates the Global Biosimilars Market
Europe accounted for the largest regional share of the biosimilars market in 2024. The region’s leadership is supported by favorable government policies, established regulatory pathways, increasing healthcare cost pressures, and strong investment in biosimilar development.
Countries including Germany, France, Italy, Spain, and the UK have played an important role in biosimilar adoption and market development. The European regulatory environment has supported the approval and commercialization of biosimilars across multiple therapeutic categories, improving access to biologic treatments while creating opportunities for pharmaceutical manufacturers.
The continued expansion of biosimilar portfolios and growing competition among suppliers are expected to reinforce Europe’s position in the global market.
Competitive Landscape
Key players operating in the biosimilars market include Sandoz Group AG, Pfizer Inc., Amgen Inc., Celltrion, Inc., Biocon, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, and STADA Arzneimittel AG.
These companies are focusing on expanding biosimilar portfolios, strengthening manufacturing capabilities, pursuing regulatory approvals, and developing biosimilars across oncology, autoimmune diseases, diabetes, and other high-value therapeutic areas.
Related Reports:
Active Pharmaceutical Ingredient Market – Global Forecast to 2030
Biomarkers Market – Global Forecast to 2031
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Biosimilars Market to Reach USD 72.29 Billion by 2035, Driven by Rising Demand for Affordable Biologic Therapies
